Artivion today announced FDA premarket application (PMA) approval of its PerClot absorbable hemostatic system designed to control bleeding in specific surgical procedures. The Atlanta-based company will transfer full ownership to Baxter , following a sale agreement that occurred in July 2021. Artivion anticipates receiving an $18.75 million milestone payment under the terms of the agreement. […]
Artivion
Artivion stops mechanical aortic valve clinical trial on the advice of Data and Safety Monitorting Board
Artivion (NYSE:AORT) this week stopped the Proact Xa clinical trial that was designed to determine if patients with an On-X mechanical aortic valve can be maintained safely and effectively on apixaban. The decision to stop the trial was based on the recommendation of the independent Data and Safety Monitoring Board (DSMB). The recommendation cited a lack […]
Artivion announces positive trial results for its On-X mitral valve replacement
Artivion (NYSE:AORT) today announced positive results from a clinical trial for its On-X mechanical mitral valve replacement (MVR). Atlanta-based Artivion (formerly CryoLife) published results in The Annals of Thoracic Surgery. The Proact clinical trial, a multicenter, non-inferiority, two-arm study assessed whether, after an On-X MVR, patients could be safely managed with lower-intensity warfarin plus aspirin. […]
CryoLife announces corporate rebrand, changes name to Artivion
CryoLife today announced that it is rebranding itself and changing its name to Artivion, effective immediately. The Kennesaw, Georgia-based company’s new name, derived from the words ‘aorta,’ ‘innovation’ and ‘vision,’ reflects its focus on creating devices to treat aortic disease. The company will also change its ticker symbol on the New York Stock Exchange to […]
